Shire PLC (SHPG.OQ)
16 Feb 2018
* SHIRE ANNOUNCES FDA ACCEPTANCE OF SBLA FOR CINRYZE® FOR PEDIATRIC HEREDITARY ANGIOEDEMA USE
LONDON Shire, which is splitting its rare disease and hyperactivity drugs into separate units, said 2018 sales would grow in mid-single figures and profits would rise at an even slower pace.
* Shares pare losses to trade broadly flat (Adds further CEO comments, reaction, updates shares)
LONDON, Feb 14 Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.
* SHIRE - U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR INVESTIGATIONAL SHP647 FOR TREATMENT OF PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
* AB BIOSCIENCES AND SHIRE ENTER INTO AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF AB BIOSCIENCES' PRIM PROGRAM
* THOMAS DITTRICH WILL ASSUME HIS ROLE AS CHIEF FINANCIAL OFFICER
BRIEF-Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A
* SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A
LONDON Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.
LONDON Shire ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.
|Novartis AG (NOVN.S)||CHF79.68||--|
|Eli Lilly and Co (LLY.N)||$78.97||+0.95|
|Catalyst Biosciences Inc (CBIO.OQ)||$31.08||-2.01|
|Abbott Laboratories (ABT.N)||$60.17||+0.67|
|Actelion Ltd (ATLN.S)||--||--|
|Supernus Pharmaceuticals Inc (SUPN.OQ)||$38.35||-0.80|
|Salix Pharmaceuticals, Ltd. (SLXP.OQ)||--||--|
|ARYx Therapeutics, Inc. (ARYX.PK)||$0.00||--|
|Innoviva Inc (INVA.OQ)||$16.74||-0.06|
|Sucampo Pharmaceuticals, Inc. (SCMP.OQ)||--||--|
Earnings vs. Estimates
- Now is the perfect time to buy these 3 healthcare stocks!
- 2 'must-have' healthcare stocks after today's updates?
- Simply the best growth stocks in the FTSE 100?
- Are these 3 Brexit beaters set to fly after today's news?
- Are these 3 stocks due for a serious price correction?
- Should you buy Shire plc, Marks and Spencer Group plc and Amec Foster Wheeler plc following today's news?